EP1814872A1 - Substituierte [(phenylethanoyl)amino] benzamide und deren verwendung zur behandlung von inflammatorischen sowie herz-kreislauf-erkrankungen - Google Patents

Substituierte [(phenylethanoyl)amino] benzamide und deren verwendung zur behandlung von inflammatorischen sowie herz-kreislauf-erkrankungen

Info

Publication number
EP1814872A1
EP1814872A1 EP05813330A EP05813330A EP1814872A1 EP 1814872 A1 EP1814872 A1 EP 1814872A1 EP 05813330 A EP05813330 A EP 05813330A EP 05813330 A EP05813330 A EP 05813330A EP 1814872 A1 EP1814872 A1 EP 1814872A1
Authority
EP
European Patent Office
Prior art keywords
benzothien
substituents
alkyl
amino
naphth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05813330A
Other languages
German (de)
English (en)
French (fr)
Inventor
Ulf Brüggemeier
Petros Gatsios
Mark Meininghaus
Leila Telan
Elisabeth Woltering
Martina Wuttke
Hartmut Beck
Nils Griebenow
Frank. SÜSSMEIER
Johannes KÖBBERLING
Axel Kretschmer
Niels Svenstrup
Marcus Bauser
Wahed Moradi
Siegfried Zaiss
Claudia Hirth-Dietrich
Barbara Albrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1814872A1 publication Critical patent/EP1814872A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to substituted [(phenylethanoyl) amino] benzamides and processes for their preparation and their use for the preparation of medicaments for the treatment and / or prophylaxis of diseases, in particular of inflammatory diseases, such as e.g. Dermal, respiratory and cardiovascular disorders, e.g. Arteriosclerosis and coronary heart disease.
  • inflammatory diseases such as e.g. Dermal, respiratory and cardiovascular disorders, e.g. Arteriosclerosis and coronary heart disease.
  • WO 02/070471 claims structurally similar compounds as factor Xa and factor VIIa inhibitors, inter alia for the treatment of thrombosis, inflammatory diseases and arteriosclerosis.
  • WO 98/47885 claims structurally similar compounds as combined 5HT1A, 5HT1B and 5HTl D receptor antagonists for the treatment of central nervous system disorders.
  • Interleukin-8 belongs to the class of pro-inflammatory chemokines with the ability to attract leukocytes. The role of IL-8 in various inflammatory diseases is well described. The biological effects of IL-8 are mediated via binding to two specific receptors, CXCR1 and CXCR2, on the cell surface of target cells (Baggiolini M, Annu Rev Immunol 1997, 15, 675-705, Baggiolini M, J Int Med 2001 , 250, 91-104).
  • the inflammatory component in the pathophysiology of arteriosclerosis is generally recognized. This is also triggered by inflammatory cells (T cells, monocytes, macrophages) and secreted mediators (cytokines, chemokines) (Libby P., Nature 2002, 420, 868-874, Boisvert WA, Trends Cardiovasc Med 2004, 14, 7 -18).
  • T cells inflammatory cells
  • cytokines, chemokines secreted mediators
  • the inflammatory vascular changes are caused by the reaction of migrating monocytes with pathogenic lipoproteins in the arterial wall.
  • An antagonist of the IL-8 receptor would stop macrophage accumulation in the lesions and would thus be useful for the treatment of arteriosclerosis.
  • IL-8 receptor antagonists could find application in any disease involving activated monocytes, macrophages, or lymphocytes, since all of these cells express the receptor.
  • the invention relates to compounds of the formula
  • Y is a bond, methanediyl, sulfur or oxygen
  • R 1 is biphenyl-4-yl, where in biphenyl-4-yl 1 to 3 carbon atoms may be replaced by nitrogen,
  • X is N, O or S
  • the phenyl ring is attached via the 4 or 5 position if the five-membered ring is bonded to the carbon atom via the 2-position, or the phenyl ring is bonded via the 5-position if the five-membered ring is bonded to the carbon atom via the 3-position .
  • W is C or N
  • V is N, O or S
  • * is the point of attachment to the carbon atom, and the group is attached to the carbon atom via the 2, 3, 5 or 6 position,
  • the group is attached to the carbon atom via the 2, 3, 5 or 6 position,
  • radicals R 1 can be substituted by 1 to 3 substituents, the substituents being selected independently of one another from the group consisting of hydroxy, amino, halogen, cyano, trifluoromethyl, trifluoromethoxy, C 1 -C 6 -alkyl, C 1 -C O - alkoxy, Ci-C ⁇ alkylamino, hydroxycarbonyl, Ci-C ⁇ alkoxycarbonyl, aminocarbonyl, C 1 - C ⁇ alkylaminocarbonyl, Ci-C ö alkylcarbonyl and Ci-C ⁇ -Alkylcarbonylammo,
  • R 2 is hydrogen, C 1 -C 6 -alkyl or C 3 -C 7 -cycloalkyl
  • R 3 is C 3 -C 7 -cycloalkyl or optionally substituted by up to five fluorine-substituted C 1 -C 4 -alkyl,
  • R 7 is a group of the formula
  • R 4, R 5 and R 6 gen independently hydrogen, hydroxy, amino, Halo ⁇ , cyano, Trifiuormethyl, trifluoromethoxy, Ci-C ⁇ alkyl, C 1 -Co -alkoxy, Ci-C ö alkylamino, C 3 - C 7 -cycloalkyl, 5- to 7-membered heterocyclyl, Ce- Qo-aryl, 5- or 6-membered heteroaryl, hydroxycarbonyl, C 1 -C 6 -cycloalkyl,
  • cycloalkyl, heterocyclyl, aryl and heteroaryl may be substituted by 1 to 3 substituents, the substituents being selected independently of one another from the group consisting of hydroxy, amino,
  • R 4 and R 5 are attached to adjacent carbon atoms and form a -O-CH 2 -CH 2 -O- bridge,
  • heteroaryl may be substituted by 1 to 3 substituents, wherein the substituents are independently selected from the group consisting of hydroxy, amino, halogen, cyano, trifluoromethyl, trifluoromethoxy, Ci-C 6 alkyl, Ci-C 6 alkoxy and C 1 -C 6 -alkylamino,
  • Compounds of the invention are the compounds of the formula (Ia) and (I) and their salts, solvates and solvates of the salts, as well as those of the formula (Ia) and (I), hereinafter referred to as the exemplary embodiment (e) compounds and salts thereof , Solvates and solvates of the salts, as far as the compounds of formula (Ia) and (I) mentioned below are not already salts, solvates or solvates of the salts.
  • the compounds according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers). The invention therefore relates to the enantiomers or diastereomers and their respective mixtures. From such mixtures of enantiomers and / or diastereomers, the stereoisomerically uniform components can be isolated in a known manner.
  • the present invention encompasses all tautomeric forms.
  • Salts in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. However, also included are salts which are not suitable for pharmaceutical applications themselves, but can be used, for example, for the isolation or purification of the compounds according to the invention.
  • Physiologically acceptable salts of the compounds of the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of Hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • Salts of Hydrochloric acid hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, trifluoroacetic acid, propionic acid
  • Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having from 1 to 16 carbon atoms.
  • alkali metal salts for example sodium and potassium salts
  • alkaline earth salts for example calcium and magnesium salts
  • ammonium salts derived from ammonia or organic amines having from 1 to 16 carbon atoms such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having from 1 to 16 carbon atoms.
  • Atoms such as, by way of example and by way of preference, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine.
  • solvates are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water.
  • the free base of the salts of the compounds according to the invention can be obtained, for example, by addition of an aqueous base, for example dilute sodium hydroxide solution, and subsequent extraction with a solvent by methods known to the person skilled in the art.
  • an aqueous base for example dilute sodium hydroxide solution
  • a solvent for example dilute sodium hydroxide solution
  • Alkylcarbonyl and Alkylcarbonylamino stand for a linear or branched alkyl radical with usually 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms, by way of example and preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl Butyl, n-pentyl and n-hexyl.
  • Alkoxy is exemplified and preferably methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
  • Alkylamino represents an alkylamino radical having one or two (independently selected) alkyl substituents, by way of example and by preference methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexylamino, N, N Dimethylamino, NN
  • Alkylamino is, for example, a monoalkylamino radical having 1 to 3 carbon atoms or a dialkylamino radical having in each case 1 to 3 carbon atoms per alkyl substituent.
  • Alkoxycarbonyl is by way of example and preferably methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxycarbonyl.
  • Alkylaminocarbonyl is an alkylaminocarbonyl radical having one or two (independently selected) alkyl substituents, the alkyl substituents independently of one another generally having 1 to 6, preferably 1 to 4, particularly preferably 1 to 3, carbon atoms, by way of example and preferably methylaminocarbonyl, ethylaminocarbonyl, n -Propylaminocarbonyl, isopropylaminocarbonyl, tert -butylaminocarbonyl, n -pentylaminocarbonyl, n -hexylaminocarbonyl, N, N-dimethylaminocarbonyl, N, N -diethylaminocarbonyl, N -ethyl-N-methylaminocarbonyl, N -methyl-Nn-propylaminocarbonyl, N -Isopropyl-Nn-propylaminocarbonyl, N-tert-but
  • C 1 -C 3 -alkylaminocarbonyl is, for example, a monoalkylaminocarbonyl radical having 1 to 3 carbon atoms or a dialkylaminocarbonyl radical having in each case 1 to 3 carbon atoms per alkyl substituent.
  • Alkylcarbonyl is by way of example and preferably methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, isopropylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl and n-hexylcarbonyl.
  • Alkylcarbonylamino is by way of example and preferably methylcarbonylamino, ethylcarbonylamino, n-propylcarbonylamino, isopropylcarbonylamino, tert-butylcarbonylamino, n-pentylcarbonylamino and n-hexylcarbonylamino.
  • Cycloalkyl is a cycloalkyl group having usually 3 to 7, preferably 5 to 7 carbon atoms, by way of example and preferably cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Aryl is a mono- or bicyclic aromatic radical having generally 6 to 10 carbon atoms, by way of example and preferably aryl are phenyl and naphthyl.
  • Heteroaryl is an aromatic, monocyclic radical having usually 5 or 6 ring atoms and up to 4, preferably up to 2 heteroatoms from the series S, O and N, where a nitrogen atom can also form an N-oxide, by way of example and preferably for thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, oxadiazolyl, pyrazolyl, imidazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl.
  • Heterocyclyl is a monocyclic, heterocyclic radical having usually 5 to 7 ring atoms and up to 3, preferably up to 2 heteroatoms and / or hetero groups from the series N, O, S, SO, SO 2 , where a nitrogen atom also can form an N-oxide.
  • the heterocyclyl radicals may be saturated or partially unsaturated.
  • Halogen is fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine.
  • radicals are substituted in the compounds according to the invention, the radicals may, unless otherwise specified, be mono- or polysubstituted or differently substituted. A substitution with up to three identical or different substituents is preferred. Very particular preference is given to the substitution with a substituent.
  • Preferred compounds of the formula (Ia) are those of the formula
  • Y is a bond or methanediyl
  • R 1 is biphenyl-4-yl, where in biphenyl-4-yl 1 to 3 carbon atoms may be replaced by nitrogen,
  • X is N, O or S
  • the phenyl ring is attached through the 4 or 5 position when the five-membered ring is attached to the carbon atom through the 2-position, or the phenyl ring is attached through the 5-position Position is bound when the five-membered ring is bonded to the carbon atom via the 3-position,
  • W is C or N
  • V is N, O or S
  • the group is attached to the carbon atom via the 2, 3, 5 or 6 position,
  • the group is attached to the carbon atom via the 2, 3, 5 or 6 position,
  • radicals R 1 may be substituted with 1 to 3 substituents, whereby the substituents are independently selected from the group consisting of hydroxy, amino, halogen, cyano, trifluoromethyl, trifluoromethoxy, Ci-C ö alkyl, Q-Ce -
  • R 2 is hydrogen, C 1 -C 6 -alkyl or C 3 -C 7 -cycloalkyl
  • R 3 is C 3 -C 7 -cycloalkyl or optionally substituted by up to five fluorine-substituted Ci-Gj-alkyl,
  • R 4 , R 5 and R 6 independently of one another represent hydrogen, hydroxyl, amino, halogen, cyano,
  • Cycloalkyl 5- to 7-membered heterocyclyl, C ⁇ -Cio-aryl, 5- or 6-membered heteroaryl,
  • Ci-C ö alkoxycarbonyl aminocarbonyl, Ci-C ⁇ -alkylaminocarbonyl, Ci-C ö alkylcarbonyl or Ci-C ⁇ -Alkylcarbonylamino represents,
  • cycloalkyl, heterocyclyl, aryl and heteroaryl may be substituted with 1 to 3 substituents, wherein the substituents are independently selected from the group consisting of hydroxy, amino, halogen, cyano, trifluoromethyl, Trifluor ⁇ methoxy, Ci-C ⁇ -alkyl, Ci -C ö alkoxy, Ci-C 6 -alkylamino, hydroxycarbonyl, Ci-C ⁇ - alkoxycarbonyl, aminocarbonyl, Ci-C ⁇ alkylaminocarbonyl, Cj-Ce-alkylcarbonyl, and
  • Y is a bond or methanediyl
  • R 1 is biphenyl-4-yl, l, 3-benzodioxol-5-yl, 2,3-dihydro-l, 4-benzodioxin-5-yl, 5-phenylthien-2-yl, 5-phenyl-furan -2-yl, naphth-1-yl, naphth-2-yl, quinolin-6-yl, 1-benzothien-2-yl, 1-benzothien-3-yl, 1-benzothien-5-yl, 1-benzothiene 6-yl, 1-benzofuran-2-yl or 1-benzofuran-3-yl, wherein biphenyl-4-yl, l, 3-benzodioxol-5-yl, 2,3-dihydro-l, 4-benzodioxin-5-yl, 5-phenylthien-2-yl, 5-phenyl-furan-2 -yl, naphth-1-yl, naphth-2-yl, quinolin-6-y
  • Ci-C ⁇ -alkyl C 1 -Ce- alkoxy, Ci-C ö alkylamino, hydroxycarbonyl, Ci-C ⁇ -alkoxycarbonyl, aminocarbonyl, Ci-C ⁇ -alkylaminocarbonyl, Ci -C ö alkylcarbonyl and Ci-C ö alkylcarbonylamino,
  • R 2 is 6 alkyl, hydrogen or C r C,
  • R 3 is C 3 -C 7 -cycloalkyl or optionally C 1 -C 4 -alkyl substituted with up to five fluorine,
  • R 4 , R 5 and R 6 independently of one another represent hydrogen, hydroxyl, amino, halogen, cyano,
  • Cycloalkyl 5- to 7-membered heterocyclyl, C ⁇ -Cio-aryl, 5- or 6-membered heteroaryl, hydroxycarbonyl, C 1 -C 6 -alkoxycarbonyl, aminocarbonyl, C 1 -C 6 -alkylaminocarbonyl, Q-
  • cycloalkyl, heterocyclyl, aryl and heteroaryl may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of hydroxyl, amino, halogen, cyano, trifluoromethyl, trifluoromethoxy, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, Ci-C 6 -alkylamino, hydroxycarbonyl, C r C 6 -
  • Y is a bond or methanediyl
  • R 1 is biphenyl-4-yl, l, 3-benzodioxol-5-yl, 2,3-dihydro-l, 4-benzodioxin-5-yl, 5-phenylthien-2-yl, 5-phenyl-furan -2-yl, naphth-1-yl, naphth-2-yl, quinolin-6-yl, 1-benzothien-2-yl, 1-benzothien-3-yl, 1-benzothien-5-yl, 1-benzothiene 6-yl, 1-benzofuran-2-yl or 1-benzofuran-3-yl, wherein biphenyl-4-yl, l, 3-benzodioxol-5-yl, 2,3-dihydro-l, 4-benzodioxin-5-yl, 5-phenylthien-2-yl, 5-phenyl-furan-2 -yl, naphth-1-yl, naphth-2-yl, quinolin-6-y
  • R 2 is 6 alkyl, hydrogen or C r C,
  • R 3 is C 3 -C 7 -cycloalkyl or optionally substituted by up to five fluorine-substituted CrQ-alkyl,
  • R 4, R 5 and R 6 fluoromethoxy independently hydrogen, halogen, cyano, trifluoromethyl, Tri ⁇ , Ci-C 6 alkyl, C 3 -C 7 -cycloalkyl, hydroxycarbonyl, Ci-C ö alkoxycarbonyl, aminocarbonyl, Ci -C ä alkylaminocarbonyl, Ci-C ⁇ -alkylcarbonyl or Ci-C ö -Alkylcarb- carbonylamino group,
  • cycloalkyl may be substituted with 1 to 3 substituents, wherein the substituents are independently selected from the group consisting of hydroxy, amino, halogen, cyano, trifluoromethyl, trifluoromethoxy, Q-C ⁇ -alkyl, Ci-C ⁇ -alkoxy, Ci -C ⁇ -alkylamino, hydroxycarbonyl, C 1 -C 6 -alkoxycarbonyl, aminocarbonyl, C 1 -C 6 -alkylaminocarbonyl, C 1 -C 6 -alkylcarbonyl and C 1 -C 6 -alkylcarbonylamino,
  • Y is a bond or methanediyl
  • R 1 is biphenyl-4-yl, 5-phenylthien-2-yl, naphth-2-yl, quinolin-6-yl, 1-benzothien-2-yl or 1-benzofuran-2-yl,
  • biphenyl-4-yl and naphth-2-yl may be substituted by 1 to 2 substituents, where the substituents are selected independently of one another from the group consisting of fluorine, chlorine, methoxy and ethoxy,
  • R 2 is hydrogen
  • R 3 is methyl, ethyl or isopropyl
  • R 4 , R 5 and R 6 independently of one another represent hydrogen or halogen
  • R 1 is biphenyl-4-yl, 5-phenylthien-2-yl, naphth-2-yl, quinolin-6-yl, Benzothien-2-yl or l-benzofuran-2-yl, wherein biphenyl-4-yl and naphth-2-yl may be substituted with 1 to 2 substituents, wherein the substituents are independently selected from the group consisting of fluorine, chlorine , Methoxy and ethoxy.
  • R 4 , R 5 and R 6 are independently hydrogen or halogen.
  • the invention further provides a process for the preparation of the compounds of formula (Ia), wherein
  • R 1 has the meaning given above
  • R 1 and R 2 have the abovementioned meaning
  • Y, R 3 and R 7 have the abovementioned meaning
  • X 1 is halogen, preferably iodine or bromine, or hydroxy
  • the reaction according to method [A] is generally carried out under Suzuki reaction conditions in inert solvents in the presence of a catalyst, optionally in the presence of a satzreagenzes Zu ⁇ , preferably in a temperature range from room temperature to 130 0 C at normal Kotha, K., Lahiri, D. Kashinath, Tetrahedron 2002, 58 (48), 9633-9695 and N. Miyaura, A. Suzuki, Chem. Rev. 1995, 95, 2457-2483).
  • catalysts are conventional palladium catalysts for Suzuki reaction conditions, preferably catalysts such as e.g. Dichlorobis (triphenylphosphine) palladium, tetrakistriphenylphosphmpalladium (O), palladium (II) acetate, l, r-bis [(diphenylphosphino) ferrocen] palladium II chloride (1: 1) complex with dichloromethane.
  • catalysts such as e.g. Dichlorobis (triphenylphosphine) palladium, tetrakistriphenylphosphmpalladium (O), palladium (II) acetate, l, r-bis [(diphenylphosphino) ferrocen] palladium II chloride (1: 1) complex with dichloromethane.
  • Additional reagents are for example potassium acetate, cesium, potassium or sodium carbonate, Ba ⁇ riumhydroxid, potassium tert-butoxide, cesium fluoride or potassium phosphate carried out, preference is given to additional reagents such. Potassium acetate and / or aqueous sodium carbonate solution.
  • Inert solvents are, for example, ethers, such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane, hydrocarbons, such as benzene, xylene or toluene, or other solvents, such as nitrobenzene, dimethylformamide, dimethylacetamide, dimethylsulfoxide or N-methylpyrrolidone.
  • Preferred solvents are eg Dimethylformamide, dimethylacetamide, dimethylsulfoxide or 1,2-dimethoxyethane.
  • reaction according to process [B] is carried out, if X 1 is halogen, generally in inert solvents, in the presence of a base, preferably in a temperature range from 0 0 C to 40 0 C at atmospheric pressure.
  • Inert solvents are, for example, halogenated hydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane, ethers such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane, or other solvents such as acetone, dimethylformamide, dimethylacetamide, 2-butanone or acetonitrile, is preferred Tetrahydrofuran or methylene chloride.
  • halogenated hydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane
  • ethers such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane
  • other solvents such as acetone, dimethylformamide, dimethylacetamide, 2-butanone or acetonitrile
  • bases are alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, or sodium or potassium methoxide, or sodium or potassium ethoxide or potassium tert-butoxide, or amides such as sodium amide, lithium bis (trimethylsilyl) amide or lithium diisopropylamide, or other bases such as sodium hydride, DBU, triethylamine or diisopropylethylamine, be ⁇ preferred is diisopropylethylamine.
  • alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, or sodium or potassium methoxide, or sodium or potassium ethoxide or potassium tert-butoxide
  • amides such as sodium amide, lithium bis (trimethylsilyl) amide or lithium diisopropylamide, or other bases such as sodium hydride, DBU, triethylamine or diisopropylethylamine, be ⁇ preferred is diisopropylethylamine.
  • reaction according to process [B] is carried out, if X 1 is hydroxy, generally in inert solvents, in the presence of dehydrating reagents, if appropriate in the presence of a base, preferably in a temperature range from 0 ° C. to room temperature at normal pressure.
  • dehydrating reagents examples include carbodiimides, such as N, N'-diethyl, NN'-dipropyl, NN'-diisopropyl, NN'-dicyclohexylcarbodiimide, N- (3-dimethylamino) isopropyl) -N'-ethylcarbodiimide hydrochloride (EDC) (optionally in the presence of pentafluorophenol (PFP)), N-cyclohexylcarbodiimide-N'-propyloxymethyl-polystyrene (PS-carbodiimide) or carbonyl compounds such as carbonyldiimidazole, or 1,2- Oxazolium compounds such as 2-ethyl-5-phenyl-l, 2-oxazolium-3-sulfate or 2-tert-butyl-5-methyl-isoxazolium perchlorate, or acylamino compounds such as 2-ethoxy-1-
  • Bases are, for example, alkali carbonates, e.g. Sodium or potassium carbonate, or hydrogen carbonate, or organic bases such as trialkylamines, e.g. Triethylamine, N-methylmorpholine, N-methylpiperidine, 4-dimethylaminopyridine or diisopropylethylamine.
  • the condensation is carried out with diisopropylethylamine.
  • Inert solvents are, for example, halogenated hydrocarbons, such as dichloromethane or trichloromethane, hydrocarbons, such as benzene, etromonethane, dioxane, dimethylformamide, acetonitrile or hexamethylphosphoric triamide. It is likewise possible to use mixtures of the solvents. Particularly preferred is dichloromethane or dimethylformamide.
  • the compounds of the formula (ET) are known or can be prepared by adding compounds of the formula
  • R 2 has the meaning given above, with compounds of formula (V) according to method [B].
  • the compounds of the formula (VI) are known or can be prepared by the Ver ⁇ binding of the formula
  • R 2 has the meaning given above, and
  • X 2 is halogen, preferably iodine or bromine
  • the reaction is generally carried out in inert solvents, if appropriate in the presence of a base, if appropriate in the presence of potassium iodide, preferably in a temperature range from room temperature to reflux of the solvents under atmospheric pressure.
  • Inert solvents are, for example, halogenated hydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane, ethers such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane, or other solvents such as acetone, dimethylformamide, dimethylacetamide, 2-butanone or acetonitrile, preferably tetrahydrofuran , Methylene chloride, acetone, 2-butanone, acetonitrile, dimethylformamide or 1,2-dimethoxyethane.
  • halogenated hydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane
  • ethers such as dioxane, tetrahydrofuran or 1,2-dimethoxyethane
  • other solvents such as acetone, dimethylformamide, dimethylacetamide, 2-butanone or acetonitrile,
  • bases are alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, or sodium or potassium methoxide, or sodium or potassium ethoxide or potassium tert-butoxide, or amides such as sodium amide, lithium bis (trimethylsilyl) amide or lithium diisopropylamide, or organometallic compounds such as butyllithium or phenyllithium, or other bases such as sodium hydride, DBU, preferably potassium tert-butoxide, cesium carbonate, DBU, sodium hydride, potassium carbonate or sodium carbonate.
  • the compounds of formula (VI) can be prepared by reacting the compound of formula (VII) with compounds of formula
  • R 2 has the meaning given above
  • the reaction is generally carried out in inert solvents, in the presence of a Redukti ⁇ onsffens, preferably in a temperature range from -20 0 C to reflux of the Wegsmit ⁇ tel at atmospheric pressure.
  • Inert solvents are, for example, halogenated hydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or a mixture of alcohol and water, is preferred a mixture of methanol and water.
  • halogenated hydrocarbons such as methylene chloride, trichloromethane or 1,2-dichloroethane
  • alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or a mixture of alcohol and water, is preferred a mixture of methanol and water.
  • Reducing agents are, for example, sodium borohydride or triacetoxyborohydride.
  • the compounds of the formula (IV) are known or can be prepared by reacting the compound of the formula (VI) with compounds of the formula (III) according to process [A].
  • the amide function of the compounds of the formulas (H) 3 (IV), (VI) and (VH) is optionally during the reactions with a polymeric carrier (eg rinkamide resin) or a protective group (eg 2, 4-dimethoxybenzyl) which is cleaved in the last stage according to conditions known to the person skilled in the art in order to obtain compounds of the formula (I).
  • a polymeric carrier eg rinkamide resin
  • a protective group eg 2, 4-dimethoxybenzyl
  • the compounds of the invention show an unpredictable, valuable pharmacological spectrum of action.
  • the pharmaceutical activity of the compounds according to the invention can be explained by their action as DL-8 receptor antagonists.
  • the present invention further provides for the use of the compounds according to the invention for the treatment and / or prophylaxis of diseases, preferably skin, respiratory and cardiovascular diseases, in particular arteriosclerosis.
  • diseases preferably skin, respiratory and cardiovascular diseases, in particular arteriosclerosis.
  • the compounds of the invention are suitable for the treatment and prevention of IL-8-triggered inflammatory processes, the skin diseases (eg psoriasis, (atopic) dermatitis, acne, eczema), respiratory diseases (eg asthma, bronchitis, chronic obstructive pulmonary disease , Respiratory distress syndrome), cardiovascular diseases (eg arteriosclerosis, dyslipidaemia, myocardial infarction, stroke, restenosis, reperfusion injury, thrombosis, ischaemia, coronary heart disease, pulmonary hypertension, left / right heart failure, arrhythmias, unstable angina pectoris) and infections (eg with plasmodia, hepatitis and herpes viruses), as well as arthritis (eg osteoarthritis, rheumatoid arthritis), osteoporosis, Crohn's disease, inflammatory bowel disease (eg ulcerative colitis), Alzheimer's disease, sepsis, Gingivitis, shocks (eg septic shock, endo
  • the compounds according to the invention can be used alone and if necessary also in combination with other active substances, in particular with anti-hyperlipidemic, anti-arteriosclerotic, anti-diabetic, anti-inflammatory or anti-hypertensive agents.
  • Examples include cholesterol synthesis inhibitors such as statins such as simvastatin, pravastatin and atorvastatin, antioxidants such as probucol, AGIl 067 and Bo653, PPAR modulators, fibrates such as gemfibrozil and fenofibrate, cholesterol absorption inhibitors such as ezetimibe, bile acid resins such as eg cholestyramine and colesevelam, acetylCoA acyltranferase (ACAT) inhibitors, cholesterol ester transfer protein (CETP) inhibitors, microsomal transfer protein (MTP) / apolipoprotein B- Secretion inhibitors, ileal bile acid transporter (IBAT) inhibitors, niacin and its slow-release forms, insulin (of animal, human or biotechnological origin and mixtures thereof), insulin sensitizers, calcium channel antagonists of, for example, dihydropyridine Type, diltiazeme type and verapamil type, ACE
  • Another object of the present invention is the use of Ver ⁇ compounds of the invention for the treatment and / or prophylaxis of diseases, in particular the aforementioned ge diseases.
  • Another object of the present invention is the use of Ver ⁇ compounds of the invention for the preparation of a medicament for the treatment and / or prophylaxis of Erkran ⁇ kung, in particular the aforementioned diseases.
  • Another object of the present invention are interleukin-8 receptor antagonists for the treatment and / or prophylaxis of heart failure.
  • Another object of the present invention is the use of an interleukin-8 receptor antagonist for the manufacture of a medicament for the treatment and / or prophylaxis of cardiac insufficiency.
  • Another object of the present invention is a method for the treatment and / or Pro ⁇ phylaxis of diseases, in particular the aforementioned diseases, using a therapeutically effective amount of the compounds of the invention.
  • the compounds according to the invention can act systemically and / or locally.
  • they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, na ⁇ sal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctivae otic or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • the prior art is capable of rapidly and / or modifying the compounds according to the invention which release the compounds according to the invention in crystalline and / or amorphized and / or dissolved form, for example tablets (uncoated or coated tablets, for example with enteric or delayed-dissolving or insoluble coatings which control the release of the compound according to the invention), rapidly disintegrating tablets or films / wafers, films / lyophilisates, capsules (for example hard or soft gelatine capsules), dragees, granules in the oral cavity Pellets, powders, emulsions, suspensions, aerosols or solutions.
  • Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
  • a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
  • absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
  • injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • the oral application is preferred.
  • Inhalation medicaments including powder inhalers, nebulizers
  • nasal drops solutions, sprays
  • lingual, sublingual or buccal tablets to be applied
  • films / wafers or capsules to be applied
  • suppositories ear or eye preparations
  • vaginal capsules aqueous suspensions (lotions, shake mixtures)
  • lipophilic suspensions ointments
  • creams transdermal therapeutic systems (such as patches)
  • the compounds according to the invention can be converted into the stated administration forms. This can be done in a manner known per se by mixing with inert, non-toxic, pharmaceutically suitable auxiliaries.
  • These adjuvants include, among others. Carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulfate, polyoxysorbitanoleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers ( for example, albumin), stabilizers (eg antioxidants such as ascorbic acid), dyes (eg inorganic pigments such as iron oxides) and flavor and / or odoriferous agents.
  • Carriers for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodec
  • a further subject of the present invention are medicaments which comprise at least one compound according to the invention, usually together with one or more inert, non-toxic compounds. rule, contain pharmaceutically suitable excipients, and their use for the purposes mentioned above.
  • FCS Fetal CaIf Serum Fetal Calf Serum
  • PBS Phosphate Buffered Saline Phosphate Buffered Sodium Chloride Solution
  • Method 2 Device Type MS: Micromass ZQ; Device type HPLC: HP 1100 Series; UV DAD; Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20 mm x 4 mm; Eluent A: 1 l of water + 0.5 ml of 50% formic acid, eluent B: 1 l of acetonitrile + 0.5 ml of 50% formic acid; Gradient: 0.0 min 90% A - »2.5 min 30% A -> 3.0 min 5% A -» 4.5 min 5% A; Flow: 0.0 min 1 ml / min, 2.5 min / 3.0 min / 4.5 min 2 ml / min; Oven: 5O 0 C; UV detection: 210 nm.
  • Method 3 Instrument MS: Micromass TOF (LCT); Instrument HPLC: 2-column circuit, Waters2690; Column: YMC-ODS-AQ, 50 mm x 4.6 mm, 3.0 ⁇ m; Eluent A: water + 0.1% formic acid, eluent B: acetonitrile + 0.1% formic acid; Gradient: 0.0 min 100% A -> 0.2 min 95% A ⁇ »1.8 min 25% A -» 1.9 min 10% A -> 2.0 min 5% A - »3.2 min 5% A; Oven: 4O 0 C; Flow: 3.0 ml / min; UV detection: 210 nm.
  • Method 4 Instrument: Micromass Quattro LCZ with HPLC Agilent Series 1100; Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20 mm x 4 mm; Eluent A: 1 l of water + 0.5 ml of 50% formic acid, eluent B: 1 l of acetonitrile + 0.5 ml of 50% formic acid; Gradient: 0.0 min 90% A ⁇ > 2.5 min 30% A -> 3.0 min 5% A - »4.5 min 5% A; Flow: 0.0 min 1 ml / min, 2.5 min / 3.0 min / 4.5 min 2 ml / min; Oven: 5O 0 C; UV detection: 208-400 nm.
  • Method 5 Instrument MS: Waters ZQ 2000; Instrument HPLC: Agilent 1100, 2-column circuit, Autosampler: HTC PAL; Column: YMC-ODS-AQ, 50 mm x 4.6 mm, 3.0 ⁇ m; Eluent A: water + 0.1% formic acid, eluent B: acetonitrile + 0.1% formic acid; Gradient: 0.0 min 100% A - 0.1 min 95% A - 0.8 min 25% A - 0.9 min 5% A - 1.8 min 5% A - 1.81 min 100% A - 1.9 min 100% A; Oven: 40 ° C; Flow: 3.0 ml / min; UV detection: 210 nm.
  • Method 6 Device Type MS: Micromass ZQ; Device type HPLC: Waters Alliance 2795; Column: Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20 mm x 4 mm; Eluent A: 1 l of water + 0.5 ml of 50% formic acid, eluent B: 1 l of acetonitrile + 0.5 ml of 50% formic acid; Gradient: 0.0 min 90% A -> 2.5 min 30% A -> 3.0 min 5% A ⁇ »4.5 min 5% A; Flow: 0.0 min 1 ml / min, 2.5 min / 3.0 min / 4.5 min 2 ml / min; Oven: 5O 0 C; UV detection: 210 nm.
  • Method 7 Instrument: HP 1100 with DAD detection; Column: Kromasil RP-18, 60 mm ⁇ 2 mm, 3.5 ⁇ m; Eluent A: 5 ml HCIO 4 / l water, eluent B: acetonitrile; Gradient: 0 min 2% B, 0.5 min 2% B, 4.5 min 90% B, 9 min 90% B; Flow: 0.75 ml / min; Oven: 30 ° C; UV detection: 210 nm.
  • Polymer-bound 2-iodo-5-nitrobenzamide (Polymer 1, Example 6A) is initially charged in a 2: 1 solvent mixture of dioxane and aqueous sodium carbonate solution. Add 10 equivalents of boronic acid and 0.1 equivalent of the Pd catalyst and stir at 8O 0 C overnight under argon. It is decanted off and washed three times with water, three times with DMF, twice with 0.1% sodium pyrrolidinethiocarbamate in a solvent mixture of THF and methanol (5: 1) and then alternately three times with methanol and DCM alternately. The polymer is then dried in vacuo.
  • Polymer 2 is added to a 2 molar tin dichloride solution in DMF (65 equivalents) and shaken overnight at RT. It is decanted off, washed three times each with DMF, methanol and DCM and dried in vacuo.
  • Polymer 3 is presented in DCM. Add 10 equivalents of DIEA and 5 equivalents of carbonic acid chloride and shake overnight at RT. It is decanted, washed three times with DMF and then three times with methanol and DCM and the polymer is dried in vacuo. It is mixed with a 2: 1 mixture of dioxane and a solution of 5 equivalents Ka ⁇ liumhydroxid in methanol and shaken overnight at RT. The polymer is filtered off and The polymer washes three times with water and DMF and then alternately three times with methanol and DCM. The polymer is dried in vacuo.
  • Polymer 4 is treated with concentrated TFA. It is allowed to stand for an hour and filtered from the polymer. Subsequently, the polymer is mixed with a 1: 1 mixture of TFA and DCM and allowed to stand again for one hour. It is again filtered from the polymer and the polymer is washed twice with the 1: 1 mixture of TFA and DCM. The combined filtrates are evaporated in vacuo and the crude product thus obtained is purified by preparative HPLC.
  • Non-commercially available 2- (het) arylacetic acids can be synthesized by lithiation with LDA or LiHMTS and subsequent alkylation with an alkyl halide, see Thompson, H.W .; Rashid, S.Y. J. Org. Chem. 2002, 67, 2813-2825.
  • the deprotected Rinc amide polymer is suspended in 20 ml DCM and 2.00 g (1.55 mmol, 2 equivalents) of DIEA and then 1.93 g (6.18 mmol, 2 equivalents) of 2-iodo-5-nitrobenzoic acid chloride (Example 2A) are added. It is shaken overnight at room temperature. It is then washed three times each with DMF, methanol and DCM. The resulting polymer 1 is dried in vacuo.
  • the preparation is analogous to the synthesis of the compound from Example 1 from the corresponding starting compounds.
  • the compound is prepared from quinoline-3-boronic acid and 2-iodo-5 - [(2- (3-fluorophenyl) butanoyl) amino] benzamide in 13.7 mg (23% of theory) yield in analogy to Example 1.
  • 2-iodo-5 - [(2- (3-fluorophenyl) butanoyl) amino] benzamide is prepared from 5-amino-2-iodobenzamide and 2- (3-fluorophenyl) butanoic acid under standard amide coupling conditions with HATU.
  • the compound is prepared from 4-amino-1, r: 4 ', l "-terphenyl-2-carboxamide and 2- (2-thienyl) - propionic acid in 26% yield in analogy to Example 1.
  • 4-Amino-1, r: 4 ', r ⁇ -terphenyl-2-carboxamide is prepared in analogy to the preparation of 5-amino-2- (1-benzothien-2-yl) benzamide (Example 7A and 8A).
  • the racemate is separated into the enantiomers.
  • Enantiomer separation gives 8 mg of enantiomer 37-2 from 20 mg of racemate.
  • Enantiomer separation gives 77 mg enantiomer 39-2 from 160 mg racemate.
  • the racemate is separated into the enantiomers.
  • CHO cells with mitochondrially localized aequorin are stably transfected with the human IL8B receptor and the G-alpha-16 protein.
  • Activation of the IL8B receptor with IL8 or an endogenous P2Y receptor with ATP leads to Ca 2+ release.
  • This intracellular Ca 2+ transient can be detected bioluminescently with mitochondrially localized aequorin.
  • IL8-induced Ca 2+ transients are inhibited by IL8B receptor antagonists. Substances that also inhibit ATP-induced Ca 2+ transients are nonspecific.
  • the IL8B receptor is activated by the addition of 25 ⁇ l of a 0.78-2.6nM IL8 solution in 2mM Ca-Tyrode / 0.1% BSA or the endogenous P2Y receptor is prepared by adding 25 ⁇ l of a 7.8-26 ⁇ M ATP solution in 2mM Ca. Tyrode activated. The bioluminescence is recorded at the same time. IC 50 values are calculated using dose-response curves using the Marquardt-Levenberg-Fit (Table A).
  • Test substances luminol (50 ⁇ M), Horse Radish Peroxidase (HRP; 1 U / ml) and recombinant human IL-8 (10-50 nM) are incubated with the PMN cell suspension and the emitted luminescence as RLU's (relative light units) in the luminometer measured immediately. This is considered a measure of the IL-8 induced ROS generation.
  • the area under the corresponding curve is used to determine the inhibitory activity and the half-maximal inhibitory concentration of the tested substances.
  • Cell culture CHO cells transfected with the human IL8 receptor B are cultured in DMEM medium with 10% FCS, penicillin (100 units / ml), streptomycin (100 ⁇ g / ml) and 0.4 mg / ml G418.
  • Membrane Preparation Cells are harvested subconfluently with trypsin and centrifuged at 500 xg for 5 min. The cell pellet is washed with PBS and then taken up in ice-cold assay buffer (50 mM Tris-HCl, 10 mM EDTA, 10 mM MgCl 2 , pH 7.4 including one time protease inhibitor cocktail (# 1873580, Roche)). Subsequently, the cells are homogenized with ice for 30 seconds on a polytron and centrifuged for 10 min at 500 xg at 4 0 C to remove the cell nuclei.
  • ice-cold assay buffer 50 mM Tris-HCl, 10 mM EDTA, 10 mM MgCl 2 , pH 7.4 including one time protease inhibitor cocktail (# 1873580, Roche)
  • the supernatant is then centrifuged at 100,000 xg (30 min, 4 0 C) and the membrane pellet resuspended in assay buffer.
  • the membrane preparation is frozen Kit ⁇ at -80 0 C and the protein content using the BCA assay (Pierce).
  • Receptor binding Receptor membranes (1 ⁇ g) are incubated with 0.2 nM 125 I labeled IL8 (Amersham) for 2 h in assay buffer at room temperature in the presence and absence of test substance. Receptor-bound EL8 is measured by adding WGA SPA beads (Amersham) in a Wallac scintillation counter.
  • Substances are administered 30 min (po) [10 ml / kg] or 10 min (iv) [5 ml / kg] before EL-8 stimulation.
  • the percentage of neutrophils in the total cell number is determined, the IL-8-stimulated control group and for the substances, substance-treated animals for the placebo-treated unstimulated "control group.
  • the induced by administration of substance, the percentage inhibition as well as the significance (t-test) of the IL- 8 induced neutrophil migration is calculated relative to the IL-8 treated control animals.
  • IL-8 receptor antagonists To determine the anti-atherosclerotic effect of IL-8 receptor antagonists, generally accepted animal models are used in research, such as the ApoE knockout mouse (Red ⁇ dick, RL, et al., Arterioscler, Thromb., 1994, 14, 141-147). or the LDL receptor knockout mouse (Ishibashi, S., et al., Proc Natl Acad., USA 1993, 91, 4431-4435).
  • LAD left descending coronary artery
  • a thread PROLENE 1 metric 5-0 ETHICONlH
  • EL-8 receptor antagonists begins 1-2 days after the LAD occlusion.
  • Periodic ECG and echocardiographic examinations are performed over several weeks or months to analyze the development of heart failure, with and without 11-8 receptor antagonists, in the rats.
  • Blood samples are taken regularly to determine biomarkers (eg, BNP) that are a clinically accepted measure of the development of cardiac insufficiency.
  • biomarkers eg, BNP
  • the contractility of the heart is determined with a milliliter pressure catheter in vivo, the hearts are removed and histologically characterized.
  • Other in vivo in vivo assay systems are known in the literature: Braun A. et al., Circ. Res., 90, 270-6 (2002); Wang Q.-D.
  • the substances according to the invention can be converted into pharmaceutical preparations as follows:
  • Example 1 100 mg of the compound of Example 1, 50 mg of lactose (monohydrate), 50 mg of corn starch, 10 mg of polyvinylpyrrolidone (PVP 25) (BASF, Germany) and 2 mg of magnesium stearate.
  • the mixture of the compound of Example 1, lactose and starch is granulated with a 5% solution (m / m) of the PVP in water.
  • This mixture is compressed with a conventional tablet press (for the tablet format see above).
  • a single dose of 100 mg of the compound according to the invention corresponds to 10 ml of oral suspension.
  • Example 1 The compound of Example 1 is dissolved together with polyethylene glycol 400 in the water with stirring.
  • the solution is sterile-filtered (pore diameter 0.22 ⁇ m) and filled under aseptic conditions into heat-sterilized infusion bottles. These are closed with infusion stoppers and crimp caps.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
EP05813330A 2004-11-20 2005-11-17 Substituierte [(phenylethanoyl)amino] benzamide und deren verwendung zur behandlung von inflammatorischen sowie herz-kreislauf-erkrankungen Withdrawn EP1814872A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004056078 2004-11-20
DE102005023834A DE102005023834A1 (de) 2004-11-20 2005-05-24 Substituierte[(Phenylethanoyl)amino]benzamide
PCT/EP2005/012322 WO2006053748A1 (de) 2004-11-20 2005-11-17 Substituierte [(phenylethanoyl)amino] benzamide und deren verwendung zur behandlung von inflammatorischen sowie herz-kreislauf-erkrankungen

Publications (1)

Publication Number Publication Date
EP1814872A1 true EP1814872A1 (de) 2007-08-08

Family

ID=35697101

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05813330A Withdrawn EP1814872A1 (de) 2004-11-20 2005-11-17 Substituierte [(phenylethanoyl)amino] benzamide und deren verwendung zur behandlung von inflammatorischen sowie herz-kreislauf-erkrankungen

Country Status (6)

Country Link
US (1) US7776922B2 (https=)
EP (1) EP1814872A1 (https=)
JP (1) JP2008520605A (https=)
CA (1) CA2587511A1 (https=)
DE (1) DE102005023834A1 (https=)
WO (1) WO2006053748A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003284237A1 (en) * 2002-10-16 2004-05-04 Transport Systems, Inc. Monorail sortation system
US20100256157A1 (en) * 2002-10-29 2010-10-07 Jakob Busch-Petersen Method of treatment
CA2615374A1 (en) 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド 癌の治療法
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP2203432A4 (en) * 2007-09-21 2011-04-27 Glaxosmithkline Llc PROCESSING METHOD
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
CA2757622A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
MX361692B (es) 2010-02-03 2018-12-13 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de ácido graso.
DK3362462T3 (da) 2015-10-12 2021-10-11 Advanced Cell Diagnostics Inc In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil
CN110776486B (zh) * 2019-10-23 2022-05-20 中国药科大学 一种苯并呋喃类小分子p2y14受体抑制剂，及其制备和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
AU761291B2 (en) * 1999-03-17 2003-05-29 Astrazeneca Ab Amide derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006053748A1 *

Also Published As

Publication number Publication date
DE102005023834A1 (de) 2006-05-24
WO2006053748A1 (de) 2006-05-26
US7776922B2 (en) 2010-08-17
CA2587511A1 (en) 2006-05-26
JP2008520605A (ja) 2008-06-19
US20080171786A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
DE69833073T2 (de) CCR-3-Rezeptor-Antagonisten
DE60222409T2 (de) Trizyklische verbindungen, nützlich als angiotensin ii agonisten
EP1814872A1 (de) Substituierte [(phenylethanoyl)amino] benzamide und deren verwendung zur behandlung von inflammatorischen sowie herz-kreislauf-erkrankungen
EP1572642A1 (de) 3-pyrrolyl-harnstoff- derivate und ihre verwendung als antivirale mittel
WO2006063813A2 (de) 3-arylalkyl-und-3-heteroarylalkyl-substituierte-1,2,4-triazin-5(2h)-one
EP1644353A1 (de) Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
WO2006063811A2 (de) Substituierte 1,2,4-triazin-5(2h)-one
DE10147672A1 (de) Substituierte 2,5-Diamidoindole und ihre Verwendung
DE102006009928A1 (de) Substituierte Arylsulfonamide
EP1853582B1 (de) Heterocyclylamid-substituierte imidazole
DE602004009056T2 (de) N-(2-phenylethyl)sulfamid-derivate als integrin-alpha4-antagonisten
EP1562913B1 (de) Substituierte chinazoline als antivirale mittel, insbesondere gegen cytomegaloviren
EP1648447A1 (de) Pyrazoline als par-1-antagonisten zur behandlung von herz-kreislauf-erkrankungen
WO2006063791A1 (de) 3-benzylthio-1,2,4-triazin-5 (2h) -one als paf-ah inhibitoren
DE10352499A1 (de) Substituierte Dihydrochinazoline II
EP1748997A1 (de) Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE69714019T2 (de) 1,4-dihydropyridin-verbindungen als bradykinin-antagonisten
WO2006063812A1 (de) 3-cycloalkyl-1,2,4-triazin-5(2h)-one
EP1476164B1 (de) Chinoxalinone und ihre verwendung insbesondere in der behandlung von cardiovaskularen erkraunkungen
EP1732901B1 (de) 4-aminocarbonylamino-substitutierte imidazolverbindungen mit antiviraler wirkung
DE102004010545A1 (de) Pyrazoline
EP2563762B1 (de) Verfahren zur herstellung substituierter pyridin- 2 - one
DE102005033103A1 (de) Heterocyclylamid-substituierte Thiazole, Pyrrole und Thiophene
DE102004014061A1 (de) Amid-substituierte 1,2,4-Triazin-5(2H)-one
DE102007013812A1 (de) Neue Inhibitoren van Aspartylproteasen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070620

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MEININGHAUS, MARK

Inventor name: TELAN, LEILA

Inventor name: SVENSTRUP, NIELS

Inventor name: GATSIOS, PETROS

Inventor name: BECK, HARTMUT

Inventor name: ZAISS, SIEGFRIED

Inventor name: KRETSCHMER, AXEL

Inventor name: WOLTERING, ELISABETH

Inventor name: SUESSMEIER, FRANK.

Inventor name: WUTTKE, MARTINA

Inventor name: KOEBBERLING, JOHANNES

Inventor name: BRUEGGEMEIER, ULF

Inventor name: ALBRECHT, BARBARA

Inventor name: BAUSER, MARCUS

Inventor name: MORADI, WAHED

Inventor name: GRIEBENOW, NILS

Inventor name: HIRTH-DIETRICH, CLAUDIA

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20100726

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110210